VHL Antikörper (AA 101-213) (Cy5.5)
-
- Target Alle VHL Antikörper anzeigen
- VHL (Von Hippel-Lindau Tumor Suppressor, E3 Ubiquitin Protein Ligase (VHL))
-
Bindungsspezifität
- AA 101-213
-
Reaktivität
- Human
-
Wirt
- Kaninchen
-
Klonalität
- Polyklonal
-
Konjugat
- Dieser VHL Antikörper ist konjugiert mit Cy5.5
-
Applikation
- Flow Cytometry (FACS), Immunofluorescence (Cultured Cells) (IF (cc)), Immunofluorescence (Paraffin-embedded Sections) (IF (p))
- Kreuzreaktivität
- Human
- Homologie
- Mouse,Rat,Dog,Cow
- Aufreinigung
- Purified by Protein A.
- Immunogen
- KLH conjugated synthetic peptide derived from human VHL
- Isotyp
- IgG
- Top Product
- Discover our top product VHL Primärantikörper
-
-
- Applikationshinweise
-
FCM 1:20-100
IF(IHC-P) 1:50-200
IF(IHC-F) 1:50-200
IF(ICC) 1:50-200 - Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
- Format
- Liquid
- Konzentration
- 1 μg/μL
- Buffer
- Aqueous buffered solution containing 0.01M TBS ( pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol.
- Konservierungsmittel
- ProClin
- Vorsichtsmaßnahmen
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.
- Lagerung
- -20 °C
- Informationen zur Lagerung
- Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.
- Haltbarkeit
- 12 months
-
- Target
- VHL (Von Hippel-Lindau Tumor Suppressor, E3 Ubiquitin Protein Ligase (VHL))
- Andere Bezeichnung
- Vhl/Hrca1 (VHL Produkte)
- Synonyme
- HRCA1 antikoerper, RCA1 antikoerper, VHL1 antikoerper, pVHL antikoerper, BcDNA:RH61560 antikoerper, CG13221 antikoerper, DVhl antikoerper, Dmel\\CG13221 antikoerper, Dvhl antikoerper, VHL antikoerper, d-VHL antikoerper, d-vhl antikoerper, dVHL antikoerper, dmVHL antikoerper, vhl antikoerper, rca1 antikoerper, vhl1 antikoerper, hrca1 antikoerper, zgc:158722 antikoerper, Vhlh antikoerper, von Hippel-Lindau tumor suppressor antikoerper, von Hippel-Lindau antikoerper, von Hippel-Lindau tumor suppressor, E3 ubiquitin protein ligase antikoerper, von Hippel-Lindau disease tumor suppressor antikoerper, VHL antikoerper, Vhl antikoerper, vhl antikoerper, CpipJ_CPIJ009992 antikoerper
- Hintergrund
-
Synonyms: Von Hippel Lindau, von Hippel-Lindau syndrome protein homolog, Hippel-Lindau disease tumor suppressor VHL, von Hippel-Lindau tumor suppressor isoform 1, VHL, HRCA1, RCA1, VHL1, von Hippel-Lindau disease tumor suppressor isoform 2,pVHL, pVHL, G7 protein, Elongin binding protein, Protein G7, VHL 1, VHL_HUMAN,VHL1, VHLH, Von Hippel Lindau disease tumor suppressor, von Hippel Lindau syndrome, von Hippel Lindau tumor suppressor, Von Hippel-Lindau disease tumor suppressor.
Background: Von Hippel-Lindau syndrome (VHL) is a dominantly inherited familial cancer syndrome predisposing to a variety of malignant and benign tumors. A germline mutation of this gene is the basis of familial inheritance of VHL syndrome. The protein encoded by this gene is a component of the protein complex that includes elongin B, elongin C, and cullin-2, and possesses ubiquitin ligase E3 activity. This protein is involved in the ubiquitination and degradation of hypoxia-inducible-factor (HIF), which is a transcription factor that plays a central role in the regulation of gene expression by oxygen. RNA polymerase II subunit POLR2G/RPB7 is also reported to be a target of this protein. Alternatively spliced transcript variants encoding distinct isoforms have been observed. [provided by RefSeq].
- Gen-ID
- 7428
- Pathways
- Tube Formation, Signaling Events mediated by VEGFR1 and VEGFR2, Ubiquitin Proteasome Pathway
-